Teva Focuses on Central Nervous System, Respiratory Drugs

Teva Pharmaceutical Industries Ltd. shares fell the most in 16 months on investor disappointment with Chief Executive Officer Jeremy Levin’s plan to replace revenue from branded drugs losing patent protection in the next three years.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.